Sandoz Takes Enbrel Fight To The US Supreme Court

Federal Circuit Decisions Last Year Leave Potential Eight-Year Wait On Etanercept

 
• By Dean Rudge

Sandoz had hinted that further legal action was viable as it looks to introduce biosimilar competition to Amgen’s Enbrel blockbuster in the US. The Novartis subsidiary has now taken its fight to the very highest court.

US-Supreme-Court_V1_1200
Sandoz is seeking US Supreme Court Review of the Fed. Cir.'s 1 July 2020 decision. • Source: Shutterstock

More from Biosimilars

More from Products